Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,360.2
12.3 (0.37%)

 

  • STI Straits Times Index
    3,360.2
    12.3 (0.37%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,669.4
    -3.0 (-0.18%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,538.3
    -16.6 (-0.06%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,936.0
    -6.1 (-0.21%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,526.2
    -159.7 (-0.74%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,402.2
    -16.0 (-0.25%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,083.6
    1.2 (0.06%)
    Index delayed 20 minutes
  • XAO XAO
    6,752.7
    6.5 (0.10%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 245.3M
  • Value: 251.7M
  • Rise: 150
  • Fall: 79
  • Unch: 608

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Asian Pay Tv Tr0.191+0.005
Sino Grandness0.048+0.003
Koh Eco0.053+0.006
SunMoonFood^0.053+0.001
Anchor Resources0.015+0.001
IEV0.040+0.003
ThaiBev0.845-
Spackman0.017-
SPH2.270-0.050
FJ Benjamin^0.038+0.003

World Indices

World Indices
Name Last Change
Nasdaq 8,258.2 +14.1
HSI 28,540.4 -14.5
HSCEI 10,814.0 -25.0
Jakarta 6,402.4 -15.8
Nikkei 225 21,526.2 -159.7
SSE Comp 2,936.0 -6.1
Shanghai A 3,075.2 -6.4
Shanghai B 290.8 -0.9
ShenZhen A 1,642.9 -1.4
ShenZhen B 976.4 -3.3
Taiwan W 10,881.6 +5.2
PSE Comp 0.0
KOSPI 2,083.8 +1.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

CORBUS PHARMACEUTICALS HOLDINGS IN CORBUS PHARMACEUTICALS HOLDINGS IN
Updated on 15 Jul 2019 (End of trading day)
Last (USD): 6.540 Change: -0.070 High: 6.590 Remarks: -
Change (%): -1.06 Low: 6.330
Open 6.580 Yesterday's Close 6.61
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 676,569 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.86374 Trailing EPS (USD) e -1.08931 NAV (USD) b 0.6563
PE a - Trailing PE f - Price / NAV b 9.9650
Dividend (USD) d - Cash In Hand (USD) g 1.3951 Issued & Paid-up Shares c 64,455,000
Dividend Yield (%) d - Price / Cash In Hand g 4.688 Treasury Shares h -
Beta - 75 Daysi 0.208 R-Squared - 75 Days(%)i 0.34 Market Cap (M) 421.536
Beta - 500 Daysi 0.023 R-Squared - 500 Days (%)i 0.01 Enterprise Value (M) 339.182
Piotroski F Score 1 Exchange Code CRBP Par Value ( $ ) n.a.
52 Weeks Volatility (%) 74.70 Free Float (%) 94.6
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 12 Apr 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 29 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CORBUS PHARMACEUTICALS HOLDINGS IN NASDAQ 421.536 - - 9.9650 -
Industry Biotechnology NASDAQ 2,255.109 128.766 98.518 5.3653 0.790
Local Peer AMGEN INC NASDAQ 107,421.928 12.797 13.303 9.9171 3.095
Local Peer GILEAD SCIENCES INC NASDAQ 86,555.089 15.867 14.690 3.9431 3.377
Local Peer CELGENE CORP NASDAQ 64,714.658 15.995 13.638 7.9259 -
Local Peer VERTEX PHARMACEUTICAL NASDAQ 45,172.061 21.548 20.963 9.5637 -
Local Peer BIOGEN INC NASDAQ 45,297.283 10.224 9.707 3.2753 -
Local Peer ILLUMINA INC NASDAQ 44,436.630 53.797 52.217 11.1510 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,694.156 13.375 13.468 3.4616 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,590.120 355.545 66.259 2.8424 -
Local Peer INCYTE CORPORATION NASDAQ 17,453.190 159.401 69.000 8.3685 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 15,040.173 - - 5.1216 -
Local Peer EXACT SCIENCES CORP NASDAQ 15,004.660 - - 19.3125 -
Local Peer SAREPTA THERAPEUTICS INC NASDAQ 11,635.504 - - 8.6281 -
Other Local Peers ARRAY BIOPHARMA INC (NASDAQ), SEATTLE GENETICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BLUEBIRD BIO INC (NASDAQ), EXELIXIS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), TILRAY INC (NASDAQ), REPLIGEN CORP (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ALKERMES PLC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), ACCELERON PHARMA (NASDAQ), GENOMIC HEALTH INC (NASDAQ), INSMED INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), NATERA INC (NASDAQ), REGENXBIO INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), OPKO HEALTH INC (NASDAQ), VERACYTE INC (NASDAQ), ALECTOR INC (NASDAQ), EPIZYME INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), RETROPHIN INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), PERSONALIS INC (NASDAQ), MACROGENICS INC (NASDAQ), OMEROS CORP (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), VANDA PHARMACE INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), UROGEN PHARMA LTD (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), SYNTHORX INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), DERMIRA INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MEDICINOVA INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), PROTHENA CORP PLC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NEXTCURE INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), IMMUNOGEN INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), AGENUS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), RESTORBIO INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), AVROBIO INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), XBIOTECH INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), SYNLOGIC INC (NASDAQ), GERON CORP (NASDAQ), ATHERSYS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), KAMADA (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), COMPUGEN (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), MANNKIND CORPORATION (NASDAQ), CHIASMA INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), SERES THERAPEUTICS (NASDAQ), AFFIMED N V (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), CHIMERIX INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), IMV INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ARDELYX INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), TOCAGEN INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), SESEN BIO INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ADURO BIOTECH INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), NOVAVAX INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), VERASTEM INC (NASDAQ), NANTKWEST INC (NASDAQ), INMUNE BIO INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), TREVENA INC (NASDAQ), EQUILLIUM INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), SAVARA INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), VERMILLION INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), INFLARX N V (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), CURIS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), COHBAR INC (NASDAQ), ORGENESIS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), ARAVIVE INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), AQUINOX PHARMACEUTICALS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), IVERIC BIO INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), VACCINEX INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ZAFGEN INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), CONTRAFECT CORP (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SENESTECH INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), BIONANO GENOMICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), BIOCEPT INC (NASDAQ), PRECIPIO INC (NASDAQ), HISTOGENICS CORP (NASDAQ), SOLIGENIX INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), VICAL INC (NASDAQ), ATYR PHARMA INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), OHR PHARMACEUTICAL INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ADVAXIS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TROVAGENE INC (NASDAQ), VAXART INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADR EA REPR 150 ORD(POST SPLIT) (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADR EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), NEURALSTEM INC (NASDAQ), OPGEN INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), CYTORI THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH (NASDAQ)
Global Peer AMGEN-T HKEx 609,936.000 9.271 9.631 7.1731 4.272
Global Peer CSL ASX 100,306.849 44.954 41.174 14.5537 1.030
Global Peer AGILENT TECHNOLOGIES INC NYSE 22,293.306 70.549 19.958 4.3499 0.850
Global Peer SINO BIOPHARM HKEx 112,772.358 10.525 10.803 3.2534 0.816
Global Peer WUXI BIO HKEx 91,815.828 122.928 122.928 10.0722 -
Global Peer BEIGENE HKEx 57,178.251 - - 4.5276 -
Global Peer 3SBIO HKEx 35,125.006 23.219 23.219 3.5756 -
Global Peer GENSCRIPT BIO HKEx 33,142.171 199.307 199.314 8.8437 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,237.956 35.693 53.682 2.2663 -
Global Peer HAOHAI BIOTEC HKEx 7,618.156 15.515 15.515 1.8498 -
Other Global Peers FRONTAGE (HKEx), VIVA BIOTECH (HKEx), ASCLETIS-B (HKEx), POLYNOVO LIMITED (ASX), MYOVANT SCIENCES LTD (NYSE), AVITA MEDICAL LTD (ASX), CKLIFE SCIENCES (HKEx), MESOBLAST LTD (ASX), NEXT SCIENCE LTD (ASX), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), ARCUS BIOSCIENCES INC (NYSE), STARPHARMA HOLDINGS LIMITED (ASX), KADMON HLDGS INC (NYSE), TELIX PHARMACEUTIC (ASX), DPHARMA (Bursa), 22ND CENTURY GROUP INC (NYSE American), ENZO BIOCHEM INC (NYSE), STANDARD DIVERSIFIED INC (NYSE American), PFENEX INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), BBI LIFE SCI (HKEx), BIOTIME INC (NYSE American), HEMISPHERX BIOPHARMA INC (NYSE American), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), CYNATA THERAPEUTICS LTD (ASX), UNI-BIO GROUP (HKEx), PORT (SET), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), RESAPP HEALTH LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), IBIO INC (NYSE American), IMMUTEP LTD (ASX), REGENT PACIFIC (HKEx), CT ENTERPRISE (HKEx), CEL-SCI CORP (NYSE American), ORTHOCELL LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), PHYLOGICA LIMITED (ASX), INVEX THERAPEUTICS LTD NPV (ASX), IMUGENE LIMITED (ASX), ZELDA THERAPEUTICS LTD (ASX), BIOTRON (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), EXTRAWELL PHAR (HKEx), BIOSINO BIO-TEC (HKEx), RHINOMED LIMITED (ASX), ORAGENICS INC (NYSE American), ONCOSIL MEDICAL LIMITED (ASX), ISORAY INC (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American), ADALTA LTD (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), KAZIA THERAPEUTICS LIMITED (ASX), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), BIONOMICS LTD (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), NANOVIRICIDES INC (NYSE American), MEMPHASYS LTD (ASX), CELLMID LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), REGENEUS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), IMMURON LIMITED (ASX), BIOXYNE LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), Suntar Eco-City^ (SGX), HOLISTA COLLTECH LIMITED (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), BENITEC BIOPHARMA LTD (ASX), ANATARA LIFESCIENCES LTD (ASX), ACTINOGEN MEDICAL LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), HAO WEN HLDGS (HKEx), MEGASUN (Bursa), QT Vascular (SGX), MGRC (Bursa), CCP TECHNOLOGIES LTD (ASX), TBG DIAGNOSTICS LTD (ASX), NOVITA HEALTHCARE LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), MEDIBIO LIMITED (ASX), BPH ENERGY LIMITED (ASX), ALCHEMIA LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.210
-3.11 %
10 Days --0.540
-7.63 %
20 Days --0.580
-8.15 %
Medium Term Return 3 Months --0.620
-8.66 %
6 Months --1.410
-17.74 %
1 Year -+1.265
+23.98 %
Long Term Return 2 Years --0.310
-4.53 %
3 Years -+3.750
+134.41 %
Annualised Return Annualised --
+32.84 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 4.500 - 9.110 Change From 1 Year Low +2.040 % Change From 1 Year Low (%) +45.33
Change From 1 Year High -2.570 % Change From 1 Year High (%) -28.21
2 Years Range 4.500 - 9.955 Change From 2 Years Low +2.040 % Change From 2 Years Low (%) +45.33
Change From 2 Years High -3.415 % Change From 2 Years High (%) -34.30
5 Years Range 1.010 - 10.780 Change From 5 Years Low +5.530 % Change From 5 Years Low (%) +547.52
Change From 5 Years High -4.240 % Change From 5 Years High (%) -39.33
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Historical Price Data

Date Open High Low Close Volume VWAP
15 Jul 2019 6.580 6.590 6.330 6.540 676,569 -
12 Jul 2019 6.680 6.740 6.570 6.610 566,807 -
11 Jul 2019 6.790 6.800 6.630 6.670 590,000 -
10 Jul 2019 6.840 6.890 6.690 6.770 442,528 -
09 Jul 2019 6.700 6.850 6.700 6.800 350,016 -
08 Jul 2019 6.840 6.890 6.700 6.750 577,247 -
05 Jul 2019 6.880 6.980 6.770 6.840 407,592 -
03 Jul 2019 6.910 6.970 6.780 6.860 297,261 -
02 Jul 2019 7.070 7.110 6.830 6.910 390,721 -
01 Jul 2019 7.000 7.130 6.900 7.080 705,781 -
28 Jun 2019 6.880 6.940 6.760 6.930 1,198,959 -
27 Jun 2019 6.710 6.910 6.710 6.860 659,044 -
26 Jun 2019 6.870 6.970 6.630 6.680 839,370 -
25 Jun 2019 7.130 7.180 6.850 6.850 701,843 -
24 Jun 2019 7.370 7.410 7.020 7.120 1,056,182 -
21 Jun 2019 7.250 7.550 7.170 7.350 1,284,669 -
20 Jun 2019 7.100 7.350 7.090 7.310 1,013,719 -
19 Jun 2019 7.040 7.110 6.913 7.050 798,233 -
18 Jun 2019 7.150 7.250 7.010 7.020 714,243 -
17 Jun 2019 6.960 7.260 6.850 7.120 1,026,492 -
14 Jun 2019 7.070 7.110 6.830 6.850 416,903 -
13 Jun 2019 6.900 7.110 6.889 7.100 798,115 -
Summary
Current 2 Weeks
(01 Jul 2019 to 15 Jul 2019)
7.000 7.130 6.330 6.540 5,004,522 -
Previous 2 Weeks
(17 Jun 2019 to 28 Jun 2019)
6.960 7.260 6.330 6.930 9,292,754 -
4 Weeks from
(17 May 2019 to 14 Jun 2019)
7.250 7.520 6.330 6.850 13,849,601 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.